|ORIGINAL RESEARCH PAPERS
|Year : 2005 | Volume
| Issue : 2 | Page : 89-93
Efficacy and safety of citalopram versus amitriptyline in the treatment of major depression
Anand Mathur, DK Sharma, Ashok Choudhary, Mahendra Jain
Department of Psychiatry, J.L.N. Medical College and Deaddiction Centre, Ajmer 205001, India
Background: Double-blind clinical trials comparing citalopram with amitriptyline or other tricyclic antidepressants are lacking in India.
Aim: To evaluate the efficacy and safety of the newer antidepressant citalopram in the treatment of major depression.
Methods: The clinical acceptability and safety profile of citalopram was assessed and compared with that of amitriptyline in 40 patients in an outpatient set-up. Patients aged 18 to 65 years who fulfilled the diagnostic criteria for a single or recurrent major depressive disorder (as defined by DSM-IV) for a minimum of 2 weeks were enrolled. Patient assessment was done at screening, baseline, end of week 1, week 2, week 3, week 4, week 5 and week 6 for efficacy and safety parameters such as Hamilton Depression Rating Scale (HDRS), Clinical Global Impression (CGI) Scale, adverse event follow up, blood pressure and pulse. Threelevel statistical analysis including ANOVA was performed on all efficacy measures.
Results: On the HDRS the percentage reduction in the mean score for the citalopram group (Group 1) was 72.12%, while that for the amitriptyline group (Group 2) was 67.93%. On the CGI-Improvement Scale, the percentage reduction at the end of the study for the citalopram group was 56.79% while in the amitriptyline group it was 44.70%. Twenty per cent of patients in Group 1 reported adverse events compared to 75% in Group 2.
Conclusions: Citalopram is effective in the treatment of major depression at the dosages range of 20-60 mg/ day and its efficacy is equivalent to that of standard tricyclic antidepressants such as amitriptyline, with a substantially better tolerability profile.
Department of Psychiatry, J.L.N. Medical College and Deaddiction Centre, Ajmer 205001
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*